RNA nucleobases (Adenine, Guanine, Cytosine, Uracil) (A, G, C, U)

RNA nucleobases—adenine (A), guanine (G), cytosine (C), and uracil (U)—are the fundamental nitrogenous components of ribonucleic acid, essential for the transcription and translation of genetic information (National Human Genome Research Institute, 2024). In a therapeutic context, these molecules serve as the structural templates for nucleoside and nucleotide analogs, a major class of drugs used extensively in oncology and virology (Galmarini et al., 2002). These therapeutic analogs mimic natural nucleobases to interfere with nucleic acid synthesis, often by inhibiting RNA polymerases or being incorporated into nascent RNA strands to cause premature chain termination or 'error catastrophe' through lethal mutagenesis (Pruijssers & Denison, 2019). While highly effective against rapidly proliferating cells and viruses, drugs targeting nucleobase pathways often exhibit significant systemic toxicity due to their impact on normal cellular division, leading to side effects like bone marrow suppression (Longley et al., 2003). Consequently, clinical management often involves monitoring metabolic enzymes such as DPD or TPMT to predict drug clearance and minimize adverse reactions (StatPearls, 2023). Beyond their role in genetic coding, these bases are also critical for cellular energy transfer and signaling, making their metabolic pathways vital targets for a wide range of pathological conditions (PubChem, 2024).

Other names

RibonucleobasesNitrogenous basesPurines and PyrimidinesRNA bases

Drugs targeting RNA nucleobase pathways typically act as antimetabolites or nucleoside analogs. They function by competitive inhibition of enzymes involved in nucleotide synthesis, incorporation into nascent RNA strands leading to premature chain termination, or the induction of lethal mutagenesis (error catastrophe) in viral or cancer cell genomes (Galmarini et al., 2002; Pruijssers & Denison, 2019).